Alzheimer’s Disease (AD): Competitive Landscape to 2026
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Alzheimer’s disease (AD) is a progressive neurodegenerative disease that is characterized by memory loss, cognitive impairment, and functional decline. The degeneration of neurons starts in the brainstem before progressing to the hippocampus, frontal lobe, amygdala, parietal lobe, and temporal lobe. The cause of AD is unknown, but it appears to be multifactorial, with most research aimed at the Aβ peptides and tau proteins. The irregular clearance and metabolism of these proteins are likely contributors to the presentation of the disease. The risk of developing AD is believed to be determined by a combination of genetic, metabolic, behavioral, and environmental factors.
This report provides an assessment of the pipeline, clinical, and commercial landscape of AD. Overall, GlobalData expects new drug approvals to drive AD market growth over the next decade (2016–2026).
Scope
GlobalData’s Alzheimer’s Disease (AD): Competitive Landscape to 2026 combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the slide deck include:
• Pipeline Assessment—regional breakdown, promising late-stage products, early-stage pipeline by molecule type
• Clinical Trials Assessment—trial breakdown by phase, leading industry and non-industry sponsors, enrollment analytics
• Commercial Assessment—leading marketed products, current and future players
• Competitive Landscape Analysis—key market events (2016–2026)
Reasons to Buy
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the global AD market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global AD market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Eisai Co.
F. Hoffmann-La Roche
Otsuka Pharmaceuticals
Eli Lilly
Ionis Pharmaceuticals
TauRx Therapeutics
Axsome Therapeutics
Accera
Novartis
AZTherapies
AB Science
Grifols
Shanghai Green Valley Pharmaceutical
Archer Pharmaceuticals
Changchun Huayang High-Tech
Intra-Cellular Therapies
Avanir Pharmaceuticals
Promis Neurosciences
Pfizer
Johnson & Johnson
AstraZeneca
Janssen
Allergan
Adamas Pharmaceuticals
Lundbeck
Merz Pharma GmbH
Icure Pharmaceutical
Shire
Chase Pharmaceuticals
Table of Contents
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.